Sagimet Biosciences Inc. (SGMT) Balance Sheet

Assets declined roughly 45% over eight consecutive quarters, almost entirely through cash consumption, since goodwill remained at zero and PPE stayed near zero throughout, meaning no asset write-downs were involved. The 2026Q2 step-change, with cash rising from $36.6M to $165.9M, appears consistent with an external capital raise, implying the balance sheet's improvement depends on continued capital market access rather than operating self-sufficiency.

The absence of goodwill and the negligible PPE base remove impairment and depreciation risk, but they also indicate Sagimet has built no manufacturing or commercial infrastructure — the asset base funds programs rather than operations. Investors are therefore underwriting a cash pile and a pipeline, with no installed asset platform that could be leveraged or liquidated independently of continued funding.

Because retained earnings are deeply negative, the entire equity balance reflects investor contributions less losses, so book value can only be sustained by narrowing losses or raising fresh capital. The rising SBC run-rate against zero revenue suggests dilution is quietly expanding the share count, which may erode per-share book value faster than the headline equity line implies.

The liquidity profile is materially stronger than peers such as AKBA at 1.13 and MDGL at 4.01, giving Sagimet unusual near-term flexibility with essentially no short-term obligations pressure. However, cash fell from $176.8M to $35.0M over eight quarters before the 2026Q2 top-up, indicating the runway is renewed by periodic raises rather than generated internally.